Shop Now Contact

Recombinant Human IFNγ protein

Cat # Size Price Quantity
63180120 μg$75
631802100 μg$210

  Bulk/Custom

Product Details

ApplicationBioassay
FormatLyophilized from sterile 50mM Tris, pH 8.0.
Expression HostE.coli
Target NameIFNγ. Interferon-γ, Immune interferon, T cell interferon, Macrophage-activating factor (MAF), Type II interferon
SpeciesHuman
accession numberNP_000610.2
SourcesA DNA sequence encoding the human IFNγ (NP_000610.2) (Gln24-Gln166) was expressed with an N-terminal Met.
Molecular WeightThe recombinant human IFNγ consists of 144 amino acids and predicts a molecular mass of 16.91 kDa. The molecular weight of this protein is around 35.4 kDa verified by SEC-MALS (Routinely tested).
Affinity TagNone
Purity≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
Regulatory StatusRUO
Endotoxin level<0.01EU per μg protein
Protein ConcentrationLyophilized
Storage and HandlingSamples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Research AreasInflammation, Antigen Presentation, Infectious Diseases, NK cells, NKT cells, T cells, Macrophages, Dendritic cells

Background Information

Human interferon-gamma (IFN-γ) is a key immunoregulatory cytokine primarily produced by activated T lymphocytes, particularly CD4⁺ Th1 cells, CD8⁺ cytotoxic T cells, and natural killer (NK) cells. It plays a central role in innate and adaptive immunity by enhancing macrophage activation, promoting antigen presentation through upregulation of MHC class I and II molecules, and driving Th1 polarization. IFN-γ is critical for host defense against intracellular pathogens such as viruses and certain bacteria, and it also contributes to immune surveillance against tumors.

Structurally, IFN-γ is a homodimeric protein, with each monomer approximately 17 kDa, forming a biologically active ~34 kDa dimer. It belongs to the type II interferon family and adopts a six α-helix bundle structure. IFN-γ signals through a heterodimeric receptor composed of IFNGR1 and IFNGR2 chains. Upon ligand binding, receptor-associated Janus kinases (JAK1 and JAK2) are activated, leading to phosphorylation of STAT1 and induction of interferon-stimulated genes. Unlike type I interferons, IFN-γ has a more specialized role in immune modulation rather than broad antiviral signaling.

Dysregulation of IFN-γ is implicated in a range of diseases. Excessive IFN-γ activity contributes to autoimmune and inflammatory disorders such as rheumatoid arthritis and certain forms of colitis, while insufficient IFN-γ responses can result in increased susceptibility to infections. IFN-γ is also involved in cytokine storm syndromes. Therapeutically, recombinant IFN-γ has been approved for conditions like chronic granulomatous disease to enhance microbial killing. Conversely, strategies to inhibit IFN-γ signaling are being explored for treating autoimmune diseases and hyperinflammatory states, highlighting its dual role as both a protective and pathogenic mediator.

Data Sheets

Recombinant Human IFNγ protein TDS

Frequently Asked Questions

What are InnoCyto's Cytokines and Growth Factors?
These are recombinantly expressed signaling proteins, including interleukins, interferons, chemokines, and growth factors, that mediate cell communication, proliferation, differentiation, and immune activation. They are produced for use as research reagents to stimulate, modulate, or study cellular responses in vitro and in vivo.
What expression systems are these proteins produced in, and does it matter for my application?
Cytokines and growth factors may be produced in mammalian, insect, or E. coli expression systems depending on the protein, and the system affects properties like glycosylation, folding, and bioactivity. Non-glycosylated proteins from E. coli are often suitable for cell culture stimulation assays, while glycosylation-dependent proteins may require mammalian- or insect-expressed versions for full biological activity — check the product page for the expression system and recommended applications.
How is bioactivity measured and confirmed for each lot?
Bioactivity is typically confirmed using a functional cell-based assay (e.g., proliferation, differentiation, or reporter assay) relevant to the specific cytokine or growth factor, and is reported as an EC50/ED50 value or specific activity (units/mg) on the Certificate of Analysis. Always reference the lot-specific CoA rather than assuming activity is identical across lots or products.
Are these proteins carrier-free, and does that matter for my experiment?
Carrier-free formulations (without BSA or other stabilizing proteins) are available for applications where carrier protein could interfere with downstream analysis, such as certain in vivo studies or proteomic work, while carrier-containing formulations offer improved stability for routine cell culture use. Choose the format that matches your assay's sensitivity to background protein content.
Can these cytokines and growth factors be used for in vivo studies?
Mouse proteins may be used in vivo, but suitability depends on your endotoxin requirements for in vivo use. Endotoxin minimum threshholds vary by product and are indicated on the individual product page. Always confirm the endotoxin specification and formulation on the Certificate of Analysis before using a product in an in vivo setting.

Have a product or application question? Consult our FAQs or contact us.